International Journal of General Medicine (May 2023)

A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014

  • Hamaguchi M,
  • Tsubata Y,
  • Yoshihara K,
  • Nakao M,
  • Amano Y,
  • Nakashima K,
  • Hotta T,
  • Okimoto T,
  • Hamaguchi S,
  • Sutani A,
  • Isobe T

Journal volume & issue
Vol. Volume 16
pp. 2125 – 2132

Abstract

Read online

Megumi Hamaguchi,1 Yukari Tsubata,1 Ken Yoshihara,1 Mika Nakao,1 Yoshihiro Amano,1 Kazuhisa Nakashima,1 Takamasa Hotta,2 Tamio Okimoto,1 Shunichi Hamaguchi,3 Akihisa Sutani,4 Takeshi Isobe1 1Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University, Izumo, Shimane, Japan; 2Department of Respiratory Medicine, Shimane Prefectural Central Hospital, Izumo, Shimane, Japan; 3Department of General Medicine, Shimane University, Izumo, Shimane, Japan; 4Sutani Respiratory Clinic, Izumo, Shimane, JapanCorrespondence: Megumi Hamaguchi, Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University, 89-1, Enyacho, Izumo-shi, Shimane, Japan, Tel/Fax +81-853-20-2581, Email [email protected]: In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investigated the onset of pneumococcal pneumonia in general practice. In Izumo, Shimane Prefecture, Japan, a public subsidy for PPSV23 inoculation began in November 2012.Patients and Methods: The subjects were pneumonia patients aged 65 and over who were admitted to a hospital in Izumo. This retrospective study analyzed the following data extracted from medical records: pneumococcal pneumonia prevalence, pneumonia severity, mortality rate, PPSV23 vaccination rate, and length of hospital stay. The 2 years before the start of the public subsidy were defined as the early phase, and the 2 years after the subsidy initiation were defined as the late phase. We compared the two phases in terms of PPSV23 vaccination rate, prevalence and severity of pneumococcal pneumonia, and mortality rate.Results: We investigated data from a total of 1188 and 1086 patients in the early and late phases, respectively. The prevalence of pneumococcal pneumonia was 21.0% and 21.3% in the early and late phases, respectively. The mortality rate from pneumococcal pneumonia was 10.4% and 5.4% in the early and late phases, respectively (p = 0.080), indicating a 50% reduction. The PPSV23 vaccination rate (p < 0.001) and the comorbidity rates of chronic respiratory disease (p = 0.022) and chronic renal disease (p < 0.001) were significantly different between the early and late phases.Conclusion: This study showed that the rate of in-hospital deaths due to pneumococcal pneumonia was halved after the PPSV23 vaccine was subsidized. The causal relationship between the pneumococcal vaccination rate and the mortality rate of pneumococcal disease was unclear. Further investigation is deemed necessary.Keywords: Streptococcus pneumoniae, pneumococcal pneumonia, vaccine, PPSV23, PCV13

Keywords